STOCKHOLM, April 8, 2024 /PRNewswire/ -- Calliditas
Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX)
("Calliditas") today announced that the Company has received a
Notice of Allowance from the United States Patent and Trademark
Office (USPTO) for patent application no. 16/760,910 entitled "Use
of NOX Inhibitors for Treatment of Cancer". This Notice of
Allowance is expected to result in the issuance of a U.S. patent
once administrative processes are completed.
The allowed claims cover a method of treating a solid tumor
presenting resistance to PD-1 inhibitor immunotherapy by
administering setanaxib in combination with a PD-1 inhibitor. The
patent, when issued, will have an anticipated expiration date in
2038.
"This is a significant value enhancing event for the global
setanaxib franchise and we are delighted that we are able to expand
product protection for setanaxib in the important area of
oncology," said CEO Renée Aguiar-Lucander.
Calliditas has corresponding applications in several additional
territories around the world, including a pending patent
application in Europe.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency
of the contact persons set out above, on April 8, 2023, at 09:00
a.m. CET.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-receives-notice-of-allowance-for-united-states-patent-application-covering-setanaxib-in-c,c3957702
The following files are available for download:
|
https://mb.cision.com/Main/16574/3957702/2715464.pdf
|
Setanaxib Patent Press
Release_ENG
|
View original
content:https://www.prnewswire.co.uk/news-releases/calliditas-receives-notice-of-allowance-for-united-states-patent-application-covering-setanaxib-in-cancer-treatment-302110166.html